T1	Limited_variation	14 21	KRAS MT
T2	Phenotype	55 71	progression-free
T3	Phenotype	76 92	overall survival
T4	Disease	105 119	NSCLC patients
T5	Chemical	153 183	platinum -based chemotherapy .
R1	decreases	Arg1:T1	Arg2:T2
R2	decreases	Arg1:T1	Arg2:T3
R3	treats	Arg1:T1	Arg2:T4
R4	influences	Arg1:T1	Arg2:T5
R5	isAssociatedWith	Arg1:T2	Arg2:T1
R6	decreases	Arg1:T2	Arg2:T3
R7	isAssociatedWith	Arg1:T2	Arg2:T4
R8	isAssociatedWith	Arg1:T2	Arg2:T5
R9	isAssociatedWith	Arg1:T3	Arg2:T1
R10	decreases	Arg1:T3	Arg2:T2
R11	isAssociatedWith	Arg1:T3	Arg2:T4
R12	isAssociatedWith	Arg1:T3	Arg2:T5
R13	isAssociatedWith	Arg1:T4	Arg2:T1
R14	decreases	Arg1:T4	Arg2:T2
R15	decreases	Arg1:T4	Arg2:T3
R16	treats	Arg1:T5	Arg2:T1
R17	decreases	Arg1:T5	Arg2:T2
R18	decreases	Arg1:T5	Arg2:T3
R19	treats	Arg1:T5	Arg2:T4
